mRNA technologies. What is their future and scope, and what are the challenges that countries might face in rolling them out? Hello and welcome to Science in5. I'm Vismita Gupta-Smith. We are talking to Dr.Soumya Swaminathan today. Soumya, talk to us about mRNA technologies. What is the future?
Recomendaciones para la eleboració de protocolos en países de bajos ingresos
South Africa has a long history of community health workers (CHWs). It has been a journey that has required balancing constrained resources and competing priorities. CHWs form a bridge between communities and healthcare service provision within health facilities and act as the cornerstone of South A...frica’s Ward-Based Primary Healthcare Outreach Teams. This study aimed to document the CHW policy implementation landscape across six provinces in South Africa and explore the reasons for local adaptation of CHW models and to identify potential barriers and facilitators to implementation of the revised framework to help guide and inform future planning.
more
Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.
Available in English, French, Spanish, Arabic, Chinese and Russian
BMJ Open Science 2021;5:e100202. doi:10.1136/
bmjos-2021-100202
Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.
Available in English, French, Spanish, Arabic, Chinese and Russian
A Estratégia Conjunta Continental Africana para a COVID-19 é sustentada pela necessidade de limitar a transmissão, prevenir mortes e reduzir os danos associados. A participação das nações africanas em ensaios clínicos é um passo essencial para garantir que sejam gerados dados suficientes so...bre a segurança e eficácia dos candidatos a vacinas mais promissores entre as populações da região.
Embora a actual actividade de ensaios clínicos COVID-19 no continente seja limitada, a África tem uma experiência e capacidades substanciais para conduzir ensaios clínicos de vacinas preventivas numa série de doenças, e muitas organizações no continente estão a trabalhar incansavelmente para ajudar a preparar ensaios adicionais sobre potenciais vacinas COVID-19.
Disponível em inglês, francês e português
more
La stratégie continentale commune africaine pour COVID-19 est sous-tendue par la nécessité de limiter la transmission, de prévenir les décès et de réduire les dommages associés. La participation des nations africaines aux essais cliniques est une étape essentielle pour garantir la productio...n de données suffisantes sur la sécurité et l'efficacité des candidats vaccins les plus prometteurs parmi les populations de la région.
Bien que l'activité actuelle des essais cliniques COVID-19 sur le continent soit limitée, l'Afrique possède une expérience et des capacités considérables pour mener des essais cliniques de vaccins préventifs contre toute une série de maladies, et de nombreuses organisations du continent travaillent sans relâche pour aider à préparer des essais supplémentaires sur des vaccins COVID-19 potentiels.
Disponible en anglais, français et portugais
more
Global procurement for COVID-19 vaccines
This article is part four in a series of explainers on vaccine development and distribution
Available in different languages
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...am-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli, can cause severe and often deadly infections that pose a particular threat for people with weak or not yet fully developed immune systems, including newborns, ageing populations, people undergoing surgery and cancer treatment.
The report highlights a worrying gap in activity against the highly resistant NDM-1 (New Delhi metallo-beta-lactamase 1), with only three antibiotics in the pipeline. NDM-1 makes bacteria resistant to a broad range of antibiotics, including those from the carbapenem family, which today are the last line of defence against antibiotic-resistant bacterial infections.
more
إن حول الإصدارات الإعلامية للنتائج الأولية للتجربة الإكلينيكية العشوائية ٍّتام) والتي تضمنت ديكساميثازون على إدراك Africa CDC المركز الأفريقي لمكافحة الأمراض و الوقاي...ة منها، UKالكبيرة التي أجريت في المملكة المتحدة () أفاد الباحثون بأن إعطاء ديكساميثازون ۱وكورتيكوستيرويد كإحدى أذرع العلاج.(عن طريق الفم أو عن طريق الحقن أدى إلى انخفاض حوالي ثلث الوفيات بين الذين يحتاجون إلى i]COVID-19المرضى المصابين بفيروس كورونا المستجد [َّتهوية ميكانيكية وحوالي الخمس للمرضى الذين يحتاجون إلى الأكسجين. إنا مدرج في قائمة الأدوية الأساسية ًديكساميثازون هو دواء عام وغير مكلف نسبيإفريقيا.لمنظمة الصحة العالمية ويستخدم على نطاق واسع في
more
14 July 2021 This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
COVID-19 vaccines have proven to be safe, ...effective and life-saving. Like all vaccines, they do not fully protect everyone who is vaccinated, and we do not yet know how well they can prevent people from transmitting the virus to others. So as well as getting vaccinated, we must also continue with other measures to fight the pandemic.
Available in English, French, Spanish, Arabic, Chinese and Russian
more
The growing understanding of how sequence information can contribute to improved public health is driving global investments in sequencing facilities and programmes. The falling cost and complexity of generating GSD provides opportunities for expanding sequencing capacity; however, challenges to wid...espread implementation remain. This document provides policy-makers and stakeholders with guidance on how to maximize the public health benefit of SARS-CoV-2 genomic sequencing activities in the short and long term as the pandemic continues to unfold. Practical considerations for the implementation of a virus genomic sequencing programme and an overview of the public health objectives of genomic sequencing are covered. This guidance focuses on SARS-CoV-2 but is applicable to other pathogens of public health concern.
more
This study examines over 20 years of CBR implementation in Nepal. It includes an overview of CBR interventions, provides analysis of approaches and activities in terms of impact and sustainability and makes recommendations for future developments in CBR. This resource is useful for people interested... in CBR in Nepal
more